Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: Glyphed oral prodrug of allopregnanolone
Aliases Glyph Allopregnanolone
Target GABA-A
Partnerships Monash University (license agreement)
Indications
major depressive disorder with or without anxious distress(Stage not disclosed)
Catalysts
— None
— None
Status note Lead product candidate. Phase 2b BUOY-1 trial in MDD with or without anxious distress initiated; Phase 1 driving simulation trial ongoing.
GlyphAgo
Phase 1 · ActiveModality: Glyphed oral prodrug of agomelatine
Aliases Glyph Agomelatine
Target MT1/MT2 + 5-HT2C
Partnerships Monash University (license agreement)
Indications
generalized anxiety disorder with sleep disturbance(Stage not disclosed)
generalized anxiety disorder(Stage not disclosed)
Catalysts
— None
— None
Status note Second product candidate. Topline data from the Phase 1 SAD, crossover and MAD portions reported in April and June 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
—
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.